knowledge -WSS

knowledge

author：focus 2025-09-30 01:12:30 - browse：66

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Medicare Advantage enrollment hits roughly 33.4 million

WSS

UnitedHealth’s board chair also owns a personal investment firm

Researchers tackle phage therapy hurdles for wider adoption

As AI regulations shape up, health tech startups beg for clarity

Studies point to risks of excluding people with obesity from drug trials

Ukraine seeks to reclaim its role as a hub for clinical trials

STAT Readout Newsletter: Today's biggest biotech updates

leisure time

knowledge

leisure time

In age of alternative facts, a scholarly course on calling out crap

Opioid cravings were reduced by anti

Heart attack and stroke risk calculators need revising

As AI regulations shape up, health tech startups beg for clarity

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Impact of Dobbs ruling felt at reproductive medicine meeting

Apple is now the first public company to be valued at $3 trillion

A new drug could help frostbite victims avoid its ravages

Walensky prepares to leave CDC — and Congress — behind

Beam Therapeutics to lay off 20% of its staff, re

hotspot

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Surprise medical billing ban raises prices elsewhere

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Medicare reduced heart disease by changing how it pays doctors

As AI regulations shape up, health tech startups beg for clarity

How climate

leisure time

explore

entertainment

knowledge